Neoadjuvant Toripalimab Plus Platinum-based Doublet for Stage III Non-small Cell Lung Cancer
Status:
Active, not recruiting
Trial end date:
2026-07-30
Target enrollment:
Participant gender:
Summary
This is an open-label, single-arm, phase II, multi-center clinical trial. Thirty patients
will be enrolled in this trial to investigate the pathological complete response rate defined
as the absence of residual tumor in lung and lymph nodes treated by chemo-immunotherapy.